The Medicines Co.'s Carbavance could be the first of three new antibiotics containing a beta-lactamase inhibitor to claim superiority versus an established drug in the same class for the treatment of complicated urinary tract infections (cUTI) – a claim that could help the company achieve its blockbuster ambitions.
Data from the Phase III TANGO 1 clinical trial showed a 98.4% overall success rate for Carbavance (meropenem-vaborbactam) versus 94%...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)